Dear Doctor Letter (Rote-Hand-Brief) for contraceptives containing dienogest and ethinylestradiol: risk of venous thromboembolism
2018.12.11
Active substance: dienogest, ethinylestradiol
The company Jenapharm GmbH & Co. KG provides information on the risk of venous thromboembolism (VTE) in women using contraceptives containing dienogest and ethinylestradiol compared to women using levonorgestrel and ethinylestradiol combinations, which are associated with a lower risk.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN